Feedback
Settings

Settings

Goto Application

1. WO2011071232 - METHOD FOR DIAGNOSIS/PROGNOSIS OF CANCERS USING AN EPIGENETIC MARKER CONSISTING OF A SPECIFIC SINGLE CPG SITE IN TTP PROMOTER AND TREATMENT OF CANCERS BY REGULATING ITS EPIGENETIC STATUS

PermaLink
Publication Number WO/2011/071232
Publication Date 16.06.2011
International Application No. PCT/KR2010/006113
International Filing Date 08.09.2010
IPC
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
C12N 15/11 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
C12N 15/1137
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1137against enzymes
C12N 2310/14
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
14interfering N.A.
C12N 2310/531
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
50Physical structure
53partially self-complementary or closed
531Stem-loop; Hairpin
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Applicants
  • KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY [KR]/[KR] (AllExceptUS)
  • YEOM, Young Il [KR]/[KR] (UsOnly)
  • SOHN, Bo Hwa [KR]/[KR] (UsOnly)
  • PARK, In Young [KR]/[KR] (UsOnly)
  • LEE, Jung Ju [KR]/[KR] (UsOnly)
  • JANG, Yejin [KR]/[KR] (UsOnly)
  • YANG, Suk-jin [KR]/[KR] (UsOnly)
  • PARK, Kyung Chan [KR]/[KR] (UsOnly)
  • YOO, Hyang-sook [KR]/[KR] (UsOnly)
  • CHOI, Jong Young [KR]/[KR] (UsOnly)
Inventors
  • YEOM, Young Il
  • SOHN, Bo Hwa
  • PARK, In Young
  • LEE, Jung Ju
  • JANG, Yejin
  • YANG, Suk-jin
  • PARK, Kyung Chan
  • YOO, Hyang-sook
  • CHOI, Jong Young
Agents
  • LEE, Won-Hee
Priority Data
10-2009-012332111.12.2009KR
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR DIAGNOSIS/PROGNOSIS OF CANCERS USING AN EPIGENETIC MARKER CONSISTING OF A SPECIFIC SINGLE CPG SITE IN TTP PROMOTER AND TREATMENT OF CANCERS BY REGULATING ITS EPIGENETIC STATUS
(FR) PROCÉDÉ DE DIAGNOSTIC/PRONOSTIC DE CANCERS EMPLOYANT UN MARQUEUR ÉPIGÉNÉTIQUE CONSISTANT EN UN SITE CPG UNIQUE SPÉCIFIQUE DANS UN PROMOTEUR TTP ET TRAITEMENT DE CANCERS PAR RÉGULATION DE SON STATUT ÉPIGÉNÉTIQUE
front page image
Abstract
(EN)
The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32ndresidue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41.
(FR)
La présente invention concerne un procédé de diagnostic et de pronostic de cancers employant un marqueur épigénétique consistant en un site CpG unique spécifique dans un promoteur TTP (Tristétraproline) et le traitement de cancers par régulation de son statut épigénétique. En particulier, la présente invention concerne un procédé de diagnostic et de pronostic du cancer du foie par mesure de la méthylation spécifique de C, le 32e résidu de la séquence d'acide nucléique représentée par SEQ. ID. NO. 41, et un procédé de traitement du cancer par sa régulation. La présente invention peut être efficacement utilisée pour le diagnostic et/ou le traitement d'un cancer du foie caractérisé par une régulation négative de TTP et une méthylation de C, le 32e résidu de la séquence d'acide nucléique représentée par SEQ. ID. NO. 41. La présente invention peut également être appliquée au diagnostic et au traitement d'autres cancers ou de maladies inflammatoires qui se caractérisent par une régulation négative de TTP et une méthylation de C, le 32e résidu de la séquence d'acide nucléique représentée par SEQ. ID. NO. 41.
Also published as
KR1020110066595
US20120251499
Latest bibliographic data on file with the International Bureau
# -